Search Results

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines, announced the publication of positive safety, immunogenicity, and efficacy data from the full cohort of patients enrolled in its GT-30 clinical trial in Nature Medicine.

Geneos Therapeutics announced the upcoming presentation of two posters sharing new clinical data from its Phase 1b/2a GT-30 study of GNOS-PV02, a personalized neoantigen DNA vaccine, in patients with advanced hepatocellular carcinoma, at the 2024 American Association for Cancer Research Annual Meeting.

Geneos Therapeutics announced that it has completed its Series A3 financing round with an additional investment of $5 million, totaling $10 million.

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines, announced that it has been nominated for the Prix Galien Startup Award for 2023.

Geneos Therapeutics today announced that it has secured $5 million in its Series A3 round.

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced updated data from GT-30, an ongoing single-arm open-label multi-center Phase 1b/2a study in second-line advanced hepatocellular carcinoma (HCC).

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced that the company has expanded its leadership team and has elected Dr. Laurent Humeau to the company’s board of directors.

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines, announced positive safety and efficacy data from the first 24 patients enrolled in GT-30.

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced that a third patient has achieved a complete response (CR) among the first 24 patients (23 evaluable) enrolled in GT-30, an ongoing single-arm open-label multi-center Phase 1b/2a study.

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of tumor neoantigen targeted personalized immunotherapies, announced that it has secured $17 million in Series A2 financing.